|
|
|
|
|
Market Research Report
SPECIAL REPORT: 2009 Chartbook of International Pharmaceutical Prices
|
This publication has been discontinued on December 27, 2011.
Below is the updated product.
Published: December, 2011
Product code: 227315
Abstract
Introduction
Payers in all countries are increasing their pressure on manufacturers to cut
prices. But prescription drug pricing and reimbursement policies vary markedly
among the leading pharmaceutical markets, so, to best determine pricing,
pharmaceutical companies need to be aware of international price
differentials. This report, featuring 33 data-rich tables and fi gures,
provides comparisons of ex-manufacturer prices for 170 best-selling drugs in
seven major markets and by select therapeutic area.
Questions Answered in This Report
- In 2008, European prescription drug prices averaged just 61% of U.S.
prices. How did prices vary among the fi ve leading European markets? Which
therapeutic areas had the highest and lowest prices relative to U.S.
prices?
- Japanese drug prices averaged 67% of U.S. prices in 2008. How many
drugs were more expensive in Japan than in the United States? What impact did
the most recent biennial price revision have on drug prices on Japan?
- The percentage price differential between the United States and other
leading pharmaceutical markets is generally much narrower for biologics than
for small-molecule drugs. How do European and Japanese prices for
monoclonal antibodies compare with prices in the United States? How great is
the percentage price differential for recombinant proteins?
- Payers in all markets will be looking to increase pressure on
manufacturers to moderate prescription drug prices. How is the U.S.
government' s health reform agenda likely to impact drug prices in the United
States? What methods are European governments using to control pharmaceutical
prices? What changes to the Japanese pricing system are currently under
discussion?
Scope
- Overall price differentials among markets: ex-manufacturer prices of 170
best-selling drugs in six major markets (France, Germany, Italy, Spain, United
Kingdom, Japan) relative to U.S. prices.
- Pricing hierarchy in individual markets: U.S. price of each of the 170
drugs under review as a percentage of average prices in the six other markets
under review; pricing hierarchy in individual European markets, Japan, and the
fi ve European markets overall as a percentage of U.S. prices.
- Price variations by therapeutic area: price variations among the 170 drugs
in our analysis divided into ten categories: cardiovascular, metabolic
disease, immune and infl ammatory disease, infectious disease, neurology,
psychiatry, antineoplastic drugs, treatments for the side effects of
chemotherapy, gastrointestinal, and genitourinary.
- Prices of biologics: prices as a percentage of U.S. prices for 23
biologics (9 monoclonal antibodies and 14 recombinant proteins) in the six
other markets under study.
- Outlook and implications: implications of the new U.S. administration' s
health reform agenda for drug prices in the United States; ongoing strict
government control of drug prices in Europe; industry calls for pricing reform
in Japan.
Table of Contents
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Overview
- Overall Price Differentials Among Markets
- Pricing Hierarchy in Individual Markets
- Price Variations by Therapeutic Area
- Cardiovascular Drugs
- Metabolic Disease Therapies
- Immune and Infl ammatory Disease Therapies
- Infectious Disease Therapies
- Neurology Drugs
- Psychiatric Drugs
- Antineoplastic Drugs
- Treatments for the Side Effects of Chemotherapy
- Gastrointestinal Drugs
- Genitourinary Drugs
- Prices of Biologics
- Outlook and Implications for the Pharmaceutical Industry
- Impact of Health Reform in the United States
- Increasing Cost-Containment Pressures in Europe
- Calls for Reform of the Pricing and Reimbursement System in Japan
- Innovative Approaches to Pricing and Reimbursement
Tables
- 1. Dosages Used for Pricing Calculations
- 2. Ex-Manufacturer Prices of Select Best-Selling Prescription Drugs
Expressed as a Percentage of U.S. Prices
- 3. U.S. Prices as a Percentage of Average Prices in the Other Six Major
Pharmaceutical Markets
- 4. French Prices as a Percentage of U.S. Prices
- 5. German Prices as a Percentage of U.S. Prices
- 6. Italian Prices as a Percentage of U.S. Prices
- 7. Spanish Prices as a Percentage of U.S. Prices
- 8. U.K. Prices as a Percentage of U.S. Prices
- 9. Average European Prices as a Percentage of U.S. Prices
- 10. Japanese Prices as a Percentage of U.S. Prices
- 11. Prices of Leading Cardiovascular Drugs in the Major Markets as a
Percentage of U.S. Prices
- 12. Prices of Leading Metabolic Disease Therapies in the Major Markets as
a Percentage of U.S. Prices
- 13. Prices of Leading Immune and Infl ammatory Disease Therapies in the
Major Markets as a Percentage of U.S. Prices
- 14. Prices of Leading Infectious Disease Therapies in the Major Markets as
a Percentage of U.S. Prices
- 15. Prices of Leading Neurological Disease Therapies in the Major Markets
as a Percentage of U.S. Prices
- 16. Prices of Leading Psychiatric Drugs in the Major Markets as a
Percentage of U.S. Prices
- 17. Prices of Leading Antineoplastic Drugs in the Major Markets as a
Percentage of U.S. Prices
- 18. Prices of Leading Treatments for the Side Effects of Chemotherapy in
the Major Markets as a Percentage of U.S. Prices
- 19. Prices of Leading Gastrointestinal Drugs in the Major Markets as a
Percentage of U.S. Prices
- 20. Prices of Leading Genitourinary Drugs in the Major Markets as a
Percentage of U.S. Prices
- 21. Prices of Leading Biologics in the Major Markets as a Percentage of
U.S. Prices
Figures
- 1. Average Pharmaceutical Prices in the Major Markets as a Percentage of
U.S. Prices
- 2. Average Prices of Leading Cardiovascular Drugs in the Major Markets as
a Percentage of U.S. Prices
- 3. Average Prices of Leading Metabolic Disease Therapies in the Major
Markets as a Percentage of U.S. Prices
- 4. Average Prices of Leading Immune and Infl ammatory Disease Therapies in
the Major Markets as a Percentage of U.S. Prices
- 5. Average Prices of Leading Infectious Disease Therapies in the Major
Markets as a Percentage of U.S. Prices
- 6. Average Prices of Leading Neurological Disease Therapies in the Major
Markets as a Percentage of U.S. Prices
- 7. Average Prices of Leading Psychiatric Disease Therapies in the Major
Markets as a Percentage of U.S. Prices
- 8. Average Prices of Leading Antineoplastic Drugs in the Major Markets as
a Percentage of U.S. Prices
- 9. Average Prices of Leading Treatments for the Side Effects of
Chemotherapy in the Major Markets as a Percentage of U.S. Prices
- 10. Average Prices of Leading Gastrointestinal Drugs in the Major Markets
as a Percentage of U.S. Prices
- 11. Average Prices of Leading Genitourinary Drugs in the Major Markets as
a Percentage of U.S. Prices
- 12. Average Prices of Leading Biologics, Small-Molecule Drugs, and
Pharmaceuticals Overall in the Major Markets as a Percentage of U.S. Prices
|
 |
